46,900€
3,30%
Echtzeit-Aktienkurs Cytokinetics
Bid:
Ask:
Echtzeit-Chart der Cytokinetics Aktie
Börsenkurse Cytokinetics
| Echtzeit Euro | - | - | - | - | 46,900€ | 3,30% |
| gettex | - | - | - | - | 46,900€ | 3,99% |
| Echtzeit USD | - | - | - | - | 48,804$ | 4,42% |
| Börse Frankfurt | - | - | - | - | 46,900€ | 5,16% |
| Nasdaq | - | - | - | - | 48,890$ | 4,60% |
| Lang & Schwarz | - | - | - | - | 46,900€ | 3,76% |
| Tradegate | - | - | - | - | 47,000€ | 4,21% |
| USA | - | - | - | - | 48,960$ | 4,75% |
| Börse Stuttgart | - | - | - | - | 44,200€ | 0,00% |
Fundamentaldaten der Cytokinetics Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 7,53 Mio. | -526,24 Mio. | -526,24 Mio. | -5,45 | - | - | 633,04 |
| 2022 [USD] | 94,59 Mio. | -388,96 Mio. | -388,96 Mio. | -4,33 | - | - | 47,02 |
| 2021 [USD] | 70,43 Mio. | -215,31 Mio. | -215,31 Mio. | -2,80 | - | - | 56,47 |
| 2020 [USD] | 55,83 Mio. | -127,29 Mio. | -127,29 Mio. | -1,97 | - | - | 59,66 |
| 2019 [USD] | 26,87 Mio. | -121,69 Mio. | -121,69 Mio. | -2,11 | - | - | 103,29 |
| 2018 [USD] | 31,50 Mio. | -106,29 Mio. | -106,29 Mio. | -1,95 | - | - | 81,47 |
| 2017 [USD] | 13,37 Mio. | -127,79 Mio. | -127,79 Mio. | -2,59 | - | - | 189,32 |
| 2016 [USD] | 106,41 Mio. | 16,45 Mio. | 16,45 Mio. | 0,39 | - | 120,26 | 17,92 |
| 2015 [USD] | 28,66 Mio. | -37,50 Mio. | -37,50 Mio. | -0,97 | - | - | 64,78 |
| 2014 [USD] | 46,94 Mio. | -14,65 Mio. | -14,65 Mio. | -0,41 | - | - | 38,63 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Cytokinetics Aktie
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.